期刊
CLINICAL INFECTIOUS DISEASES
卷 48, 期 5, 页码 503-535出版社
OXFORD UNIV PRESS INC
DOI: 10.1086/596757
关键词
-
资金
- Infectious Diseases Society of America
- Pfizer Pharmaceuticals
- Merck
- Astellas Pharma
- National Institutes of Health
- Biosynexus
- Associates of Cape Cod
- Pfizer
- Rockeby
- National Institute of Child Health and Human Development
- AstraZeneca International
- Johnson and Johnson, Medicines Company
- MedImmune
- Novartis
- Schering Plough
- Roche Diagnostics
- Amgen
- Columbia University
- Centers for Disease Control and Prevention
- Romark Laboratories
- MSD
- Schering-lough
- Gilead
- Basilea Pharmaceutica
- Viracor
- Schering
- Enzon
- Cubist Pharmaceuticals
- KV Pharmaceuticals
- Vicuron
- NATIONAL CANCER INSTITUTE [ZIASC006830] Funding Source: NIH RePORTER
Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by health care providers who care for patients who either have or are at risk of these infections. Since 2004, several new antifungal agents have become available, and several new studies have been published relating to the treatment of candidemia, other forms of invasive candidiasis, and mucosal disease, including oropharyngeal and esophageal candidiasis. There are also recent prospective data on the prevention of invasive candidiasis in high-risk neonates and adults and on the empiric treatment of suspected invasive candidiasis in adults. This new information is incorporated into this revised document.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据